Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Handa Pharmaceuticals's Net Margin % or its related term are showing as below:
ROCO:6620'
s Net Margin % Range Over the Past 10 Years
Min: -977.53 Med: -3.34 Max: 65.7
Current: 48.43
ROCO:6620's Net Margin % is ranked better than 97.71% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.635
vs ROCO:6620: 48.43
Handa Pharmaceuticals (ROCO:6620) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Handa Pharmaceuticals Net Margin % Related Terms
Handa Pharmaceuticals Net Margin % Historical Data
* Premium members only.
The historical data trend for Handa Pharmaceuticals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Handa Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Handa Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Handa Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Handa Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Handa Pharmaceuticals (ROCO:6620) has a Net Margin % of 57.65% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Handa Pharmaceuticals and its competitors. According to the industry distribution chart, Handa Pharmaceuticals ranks #22 out of 960 companies in the Drug Manufacturers industry, placing it in the top 2.3%.
Is Handa Pharmaceuticals' Net Margin % too high?
Handa Pharmaceuticals' current Net Margin % is 57.65%. The Drug Manufacturers industry median Net Margin % is 5.64. Handa Pharmaceuticals' value of 57.65% is 923.1% above this industry median. Based on the distribution chart, Handa Pharmaceuticals ranks #22 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Handa Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Handa Pharmaceuticals' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Handa Pharmaceuticals ranks #22 out of 960 companies for Net Margin %. This places Handa Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.64. Handa Pharmaceuticals' value of 57.65% is 923.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.64, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Handa Pharmaceuticals's current Net Margin % of 57.65% is 923.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Handa Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Handa Pharmaceuticals's current Net Margin % is 57.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Handa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Handa Pharmaceuticals (ROCO:6620) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$183.95, compared to a current price of NT$84.70 — trading 54% below its estimated fair value. The current Net Margin % is 57.65% and 923.1% above the Drug Manufacturers industry median of 5.64. Handa Pharmaceuticals' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Handa Pharmaceuticals (ROCO:6620), the current Net Margin % is 57.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?
Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued.
The current stock price of NT$84.70 is trading 54% below its estimated GF Value™ of NT$183.95.
GuruFocus considers Handa Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ROCO:6620:
Net Margin %: 57.65%
GF Value™: NT$183.95 vs. price of NT$84.70 (54% below fair value)
Industry Position: 923.1% above the Drug Manufacturers median (#22 of 960)
No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
75GF Score
Get the complete analysis for ROCO:6620
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6620 has been successfully added to your 
